Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemoradiotherapy in Stage IVA Nasopharyngeal Carcinoma
NCT05448885Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Sep 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05448885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448885.